Share on twitter
Share on LinkedIn
Share on Facebook
Email to a friend
Print page
This guidance provides evidence-based recommendations and good practice points for health professionals on the use of progestogen-only injectables (depot medroxyprogesterone acetate (DMPA), Depo-Provera) currently available in the UK. It is intended for any health care professional or health service providing contraception or conception advice in the UK.
This document is up-to-date
The CEU supports the self administration of Sayana Press® because of its potential benefits to women and services. It offers women greater choice and more autonomy over their contraception and fertility.
This document is up-to-date
Injectable progestogen-only contraception is a popular and effective method of contraception and until now, in the UK has largely been administered as Depo-Provera®, an intramuscular (IM) injection of 150mg medroxyprogesterone acetate (DMPA).
This document is up-to-date
Log in to view this document. 1 CPD credit can be claimed for reading the guidance. 1 CPD credit can be claimed for answering the questions.
This document is up-to-date
